Nucleus Pulposus Cell Compositions for Disc Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell-based therapies for treating intervertebral disc degeneration and low back pain struggle to effectively mimic the phenotype of native nucleus pulposus cells, particularly in surviving the nutrient-poor disc microenvironment and producing a proteoglycan-rich extracellular matrix, limiting their regenerative potential.
Innovation Solution
Development of cellular compositions comprising isolated mammalian nucleus pulposus cells with an extracellular matrix-generating phenotype, expressing CD9 and/or CD109, and optionally bound with anti-CD9 or anti-CD109 antibodies, combined with mesenchymal stem cells and/or aggrecan, to enhance ECM production and maintenance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If adult stem cells are used for cell-based therapy, then the therapy can be applied to treat disc degeneration, but the cells cannot sufficiently mimic the phenotype of native NP cells, including survival in the nutrient poor disc microenvironment and production of a proteoglycan-rich ECM
Solution Approach 1:
The patent applies parameter changes by selectively inducing and maintaining specific surface marker expressions (CD9 and CD109) on adult stem cells through controlled differentiation protocols. This transforms the cells' phenotypic parameters to match native NP cells, enabling them to survive in the nutrient-poor disc microenvironment and produce proteoglycan-rich ECM, thereby resolving the contradiction between adaptability and reliability.
Solution Approach 2:
The patent employs copying by generating adult stem cell populations that replicate the key phenotypic characteristics of native NP cells, specifically the expression of CD9 and CD109 surface markers. This copying allows the therapeutic cells to mimic the functional properties of native cells, including their ability to survive in the disc microenvironment and produce ECM, thus addressing the phenotype mimicry issue.
2Strength
If therapeutic cells are used to regenerate NP tissue, then structural and mechanical function can be restored, but the cells fail to produce sufficient proteoglycan-rich ECM
Solution Approach 1:
The patent utilizes parameter changes by modulating the expression levels of proteoglycan genes and surface markers (CD9, CD109) on therapeutic cells. This controlled parameter adjustment ensures that the cells differentiate into a phenotype that actively produces proteoglycan-rich ECM, thereby achieving both structural restoration and sufficient ECM quantity.
Solution Approach 2:
The patent applies composite materials by combining adult stem cells with specific surface marker expressions (CD9+/CD109+) and proteoglycan-producing capabilities into a composite cellular therapy. This composite approach ensures that the therapeutic preparation simultaneously provides structural support and produces sufficient proteoglycan-rich ECM to restore disc function.
Data Source
AI summary
Described are compositions containing isolated mammalian nucleus pulposus cells having an extracellular matrix (ECM)-generating phenotype and methods for making and using the disclosed compositions. The compositions disclosed herein are useful for treating back pain.